Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 46: 175-182, 2000;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (30)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Payne, R. C.
Right arrow Articles by Morris, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Payne, R. C.
Right arrow Articles by Morris, D. L.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2000;46:175-182.)
© 2000 American Association for Clinical Chemistry, Inc.

Articles

Automated Assay for HER-2/neu in Serum

Robert C. Payne1, Jeffrey W. Allard1, Linda Anderson-Mauser2, John D. Humphreys2, Donald Y. Tenney3 and David L. Morris1,a

1 Lab Testing Segment, Business Group Diagnostics, Bayer Corporation, Tarrytown, NY 10591.

2 Business Group Diagnostics, Bayer Corporation, Elkhart, IN 46514.

3 Oncogene Science Diagnostics, Inc., 80 Rogers St., Cambridge, MA 02142-1168.
a Author for correspondence. Fax 914-524-2543; e-mail david.morris.B{at}bayer.com

Background: The extracellular domain of the HER-2/neu oncogene product is increased in sera of some patients with epithelial cancers. Our aim was to develop an automated serum assay for the extracellular domain of the HER-2/neu protein.

Methods: We used a monoclonal antibody labeled with fluorescein for capture and a monoclonal Fab' fragment labeled with alkaline phosphatase for detection. Separation of bound and free detection conjugate was performed with magnetizable particles coated with monoclonal antibody to fluorescein. Alkaline phosphatase activity was measured kinetically at 405 or 450 nm.

Results: The assay was linear from 0.1 to 250 µg/L. No hook effect was evident up to 10 000 µg/L. Within-run imprecision (CV) was 0.8–1.2%, and total imprecision was 1.1–1.7%. Cross-reactivity with human epidermal growth factor receptor, which has extensive homology with HER-2/neu extracellular domain, was <0.6%. Human anti-mouse antibodies, heterophilic antibodies, and rheumatoid factor did not interfere, nor did the therapeutic monoclonal antibody Herceptin®. In 51 healthy females, the mean value was 9.3 µg/L with a range of 6.4–14.0 µg/L. No reagent lot-to-lot variability was detected over four lots of reagents tested.

Conclusion: The Bayer Immuno 1TM assay for HER-2/neu was precise and resistant to interferences, characteristics that are essential for longitudinal monitoring of cancer patients.




The following articles in journals at HighWire Press have cited this article:


Home page
 JCOHome page
L. Harris, H. Fritsche, R. Mennel, L. Norton, P. Ravdin, S. Taube, M. R. Somerfield, D. F. Hayes, and R. C. Bast Jr
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
J. Clin. Oncol., November 20, 2007; 25(33): 5287 - 5312.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. A. Perez, M. V. Karamouzis, D. V. Skarlos, A. Ardavanis, N. N. Sotiriadou, E. G. Iliopoulou, M. L. Salagianni, G. Orphanos, C. N. Baxevanis, G. Rigatos, et al.
CD4+CD25+ Regulatory T-Cell Frequency in HER-2/neu (HER)-Positive and HER-Negative Advanced-Stage Breast Cancer Patients
Clin. Cancer Res., May 1, 2007; 13(9): 2714 - 2721.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
C. White, A. Akbari, N. Hussain, L. Dinh, G. Filler, N. Lepage, and G. A. Knoll
Estimating Glomerular Filtration Rate in Kidney Transplantation: A Comparison between Serum Creatinine and Cystatin C-Based Methods
J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3763 - 3770.
[Abstract] [Full Text] [PDF]

Home page
 Protein Eng Des SelHome page
T. Olafsen, G. J. Tan, C.-w. Cheung, P. J. Yazaki, J. M. Park, J. E. Shively, L. E. Williams, A. A. Raubitschek, M. F. Press, and A. M. Wu
Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting
Protein Eng. Des. Sel., April 1, 2004; 17(4): 315 - 323.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. J. Kostler, B. Schwab, C. F. Singer, R. Neumann, E. Rucklinger, T. Brodowicz, S. Tomek, M. Niedermayr, M. Hejna, G. G. Steger, et al.
Monitoring of Serum Her-2/neu Predicts Response and Progression-Free Survival to Trastuzumab-Based Treatment in Patients with Metastatic Breast Cancer
Clin. Cancer Res., March 1, 2004; 10(5): 1618 - 1624.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
W. P. Carney, R. Neumann, A. Lipton, K. Leitzel, S. Ali, and C. P. Price
Potential Clinical Utility of Serum HER-2/neu Oncoprotein Concentrations in Patients with Breast Cancer
Clin. Chem., October 1, 2003; 49(10): 1579 - 1598.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
T. Schondorf, M. Hoopmann, M. Warm, R. Neumann, A. Thomas, U.-J. Gohring, C. Eisberg, and P. Mallmann
Serologic Concentrations of HER-2/neu in Breast Cancer Patients with Visceral Metastases Receiving Trastuzumab Therapy Predict the Clinical Course
Clin. Chem., August 1, 2002; 48(8): 1360 - 1362.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Association for Clinical Chemistry.